Here are key highlights of the Conference Call π
ANFD:
β’ In manufacturing ever plant require to convert solid into liquid by filtration. ANFD does filtration, washing of impurities, drying and is automated.
β’ Complied with CGMP
β’ Can be useful even in hazardous chemical
β’ Focus remain of launching quality product and annual innovation in products.
β’ Company has Formidable player in Glass line market.
β’ Manufactured 250 products for even single order and have already fulfilled many diverse range of order.
Order book:
β’ Both the segment continue to remain strong.
β’ Have 6-7 months order book both for filtration and Gas lined equipment.
β’ Order book is well diversified across industry.
β’ All segment Speciality Chem, Agrochem, API and Pharma and other segment are performing well
CAPEX:
β’ Process of additional of new furnace will be operational in FY 2022.
β’ CAPEX of 20 crores in in Silvassa. This makes total of 50 crore CAPEX till Fy 2022.
β’ This year CAPEX has been well presented in the below image (from IP).
Fund Raising:
β’ Company has proposed to raise 100 crores through 20 crores from equity and 80 crores from convertible warrants.
β’ This was raised from Malabar Investment Fund.
Presented the diversification in image.
Revenue Diversification:
β’ Revenue diversification across the segment has been inserted in the image.
Mgmt Comments: All the segments are going well and there is good growth from all the segment.
Investment in new CAPEX:
β’ Investment is always taken in phase wise manner, with all the manufacturing hubs.
β’ Will continue to invest as market grows.
β’ For previous CAPEX payback period was much lower.
β’ Expanding and creating space in every other segment.
Order book
Sustainability of Margin:
β’ Addition of Furnace in Ananad plant, leads to decrease in power cost.
β’ While the price increment was other factor for increase in margin.
β’ These margins are expected to be sustainable at least for the next few quarter.
Filtration and Drying:
β’ Have R&D facility which helps testing and working of product.
β’ Spherical dryer, Kilo Lab are the new innovation continue on line.
Expectation from CAPEX: Not clear on revenue number. But expect 2-2.5 ratio of Revenue / CAPEX annually.
Chemical Plant:
Chemical Plant was drown down, due to increase in residential place near to plant, while the chemical was plant was aging, which is deteriorating. The land would be use for other purpose.
β’ NSE listing on track. Currently focusing on the requirement of listing.
Accident of Yash Rasayan: Already had insurance. No impact on operational activities in HLE business.
Merger of HE Equipment: Based in Silvassa. More sort to create the all umbrella of all org. under HLE, merged the business with HLE.
Growth opportunity:
β’ Untap potential in small and mid size company and company is tapping that share.
β’ 6000 filtration capacity going well.
β’ Exports are less than 5% of the revenue.
Export:
β’ Export may not remain huge in number because company expects more growth to be delivered in domestic business than the export market.
β’ While the focus on equipment part in export continuous to be remain strong.
β’ Filtration has much untap market due to presence of many small and mid price. Hence good growth is available.
β’ Glass Line segment has competition stuff which bring, little pricing part too with quality not to be hampered. Not much pricing difference of HLE with large player.
β’ Eliminating Risk: Keep listening to customer. With need customer need company is tweaking the product.
β’ No need of debt as of now.
β’ Cash Flow utilization: Going to require of fund over period of time for CAPEX, excess cash flow will be utilized the repaying the debt.
β’ β’ β’
Missing some Tweet in this thread? You can try to
force a refresh
Business Updates:
β’ GDS and CMS segment both have contribute well.
β’ Unit 3 will be commercialized in 2 quarter of FY 2021
β’ Growth was led by Levofloxacin and Levetiracetam
β’ CMS business was the key driver for growth. Good progress from CMS
CAPEX:
β’ Expectation of 90cr this year and 60-70cr is done
β’ No further updates on CAPEX but there will be need
CMS:
β’ Growth driven by increase in commercial projects which done well. Baseline project done well
β’ CMS business could be volatile. Overall growth is positive
β’ EBIDTA margins improved, significant growth from COVID.
β’ Non - Covid business is back to pre-covid levels.
COVID test:
β’ RTPCR tests in Q2 ~ 2.7 Lac
β’ Antibody tests reported in Q2
β’ Pathology Volumes increased by 83% in Q2
β’ Added manpower in the operational end
β’ In Q2 almost 40% of the business is from Covid
β’ As the industry open up, there can be more demand of antibody test.
β’ There would be no complexity in serving the operational aspect of working with open up in the economy
- 2020 has been a year of Reset.
- Recently, economy is going through a gradual phase of recovery.
- Q2 has been as per planned
- 4 major focus 1. Progress made in the focus areas 2. Strengthening of balance sheet 3. Update on growth and business 4. Sustainability and environment
Progress on focus areas.
- Continue to focus on liquidity and equity.
- Debt to equity ratio has come down to 3.1 from 5
- Total borrowing have come down to 30k cr. from 50k cr. in 2 years
- 2k cr. would be received from PAG deal, which will make the company capital surplus
-Demand for products like Acetonitrile, DMF, NEP, DMA and TEA elevated as they are intermediates for drugs required for COVID-19 treatment
-Ramp up the production of Acetonitrile to 18-20T per day
-Receive award for export
-Subsidiary performance improved
-Demand for methyl amine increased. Separate plant for Methylamines with installed capacity of 48,000 TPA and 80% of capacity is captively used
-CAPEX of 105 crore completed and expected to commission production of Acetonitrile